Select your country

North & South America

North & South America

Argentina

Local distributor

Argentina

JUSTESA IMAGEN ARGENTINA, S.A.

Viamonte 1328, 9º piso
1053 Buenos Aires
(Argentina)

ph. +5411 4373-0629
Canada
EN | FR
Colombia

Local distributor

Colombia

AJOVECO S.A.S.

Cl. 93b #31,
Bogotá
(Colombia)

ph. +57-1-2189-200
Perù

Local distributor

Perù

REIMED, SCRL

Pasaje Villaran 192-194 U-12
Urb. Los Sauces Surquillo
Lima 15076
(Peru)

ph. 511-448-1087
Fax 511-448-3447
Uruguay

Local distributor

Uruguay

Lifenir S.A.

Justicia 2069
C 11800 Montevideo
(Uruguay)

ph. +5982-400-3020
Fax +5982-4007320
Venezuela

Local distributor

Venezuela

SUFOMECA

Torre Polar Oeste
Plaza Venezuela
Floor 7, Room 7C
Caracas
PO Box 1050
(Venezuela)

ph. +582-12-793-3222
Fax +582-12-781-1923

Europe

Europa

Bosnia-Herzegowina

Local distributor

Bosnia-Herzegowina

MARK Srl

Via S. Michele 334
34170 Gorizia - Italy

ph. +39 0481 21711
Fax +39 0481 20719
Bulgaria

Local distributor

Bulgaria

EWOPHARMA AG

73 Persenk Street
App. 27 - Floor 8
1164 Sofia
(Bulgaria)

ph. +359 29624478
Fax +359 28683968
Croatia

Local distributor

Croatia

MARK Srl

Via S. Michele 334
34170 Gorizia - Italy

ph. +39 0481 21711
Fax +39 0481 20719
Greece

Local distributor

Greece

LERIVA IMAGING S.A.

33 Pigis Avenue &
6 Anapiron Polemou Street
151 27 Melissia
Athens (Greece)

ph. +30 210-6199886
Fax +30 210 61 78 733
Hungary

Local distributor

Ungheria

EWOPHARMA REPRESENTATION OFFICE

Budakeszi ut 73/F
H-1021 Budapest
(Hungary)

ph. +36 12004650
Fax +36 13980316
Malta

Local distributor

Malta

Suratek Ltd

Concordia Place
Triq Il-Halel
Bugibba SPB2529
Malta

ph. +356 2713 1624
Romania

Local distributor

Romania

EWOPHARMA A.G. ROMANIA

B-dul Primaverii 19 -21
Sc. B - Et.1 - Sect. 1
011972 - Bucharest
(Romania)

ph. +40 212601344
Fax +40 212029327
Serbia

Local distributor

Serbia

MARK Srl

Via S. Michele 334
34170 Gorizia - Italy

ph. +39 0481 21711
Fax +39 0481 20719
Slovenia

Local distributor

Slovenia

MARK Srl

Via S. Michele 334
34170 Gorizia - Italy

ph. +39 0481 21711
Fax +39 0481 20719

Eastern Europe, Middle East & Africa

Eastern Europe, Middle East & Africa

Estonia

Local distributor

Estonia

A.Medical

Varkalu Str. 13A, Riga,
LV-1067, Latvia

ph. + 371 67113760
Fax +372 665 18 07
Ethiopia

Local distributor

Ethiopia

Caroga Pharma PVT. Ltd

P.O.Box 12627
Addis Abeba
(Ethiopia)

ph. +251 11 4654944 / 11 4161090
Fax +251 11 4654595
Ghana

Local distributor

Ghana

Cyndex Pharmacy

P.O.Box DS 1165 Dansoman
Accra
(Ghana)

ph. +233 244 366622
Fax +233-244366622 / 21850072
Israel

Local distributor

Israel

DEXCEL

Or-Akiva 30600
30600000 Israel
(Israel)

ph. +972-4-6364015
Fax +972-4-6364004
Jordan

Local distributor

Jordan

THE ARAB DRUG STORE

Khaleel Al Salem street
Amman
(Jordan)

ph. +962 6 5502995
Fax +962 6 5502984
Kenya

Local distributor

Kenya

Nairobi X-Rays Supplies Ltd.

P.O. Box 41669
Nairobi
(Kenya)

ph. +254 20446265-6-7-8
Fax +254 20 4448515/17
Lebanon

Local distributor

Lebanon

Unione Pharmaceutic. d'Orient

Rue du Musée Imm. Stephan QtrBadaro
Beyrouth
(Lebanon)

ph. +961 1 396085-6
Fax +961 1 396047
Lettonia

Local distributor

Lettonia

A.Medical

Varkalu Str. 13A, Riga
LV-1067, Latvia

ph. +371 67113760
Lithuania

Local distributor

Lithuania

A.Medical

Varkalu Str. 13A, Riga
LV-1067, Latvia

ph. +371 67113760
Mauritius

Local distributor

Mauritius

The Mauritius Pharmacy

4, Louis Pasteur Str Forest Side
(Mauritius)

ph. +230 6762435
Fax +230 675 1387
Russia

Local distributor

Russia

Joint Stock Company R-Pharm

111, bld. 1, Leninsky Avenue,
119421, Moscow, Russia
Ph. +7 (495) 956-79-37
Fax +7 (495) 956-79-38

Saudi Arabia

Local distributor

Saudi Arabia

SARABEEL COMMERCIAL EST.

Medical Division
P.O. BOX 14795
21434 Jeddah
(Saudi Arabia)

ph. +966 12657 2246
South Africa

Local distributor

South Africa

AXIM - Head Office Midrand

63 Old Pretoria Road
Halfway House Ext 2
Midrand
1685
South Africa

ph. +27 113140140
Fax +27 113140141
Uganda

Local distributor

Uganda

Kampala X-Rays Suppliers

Plot 181 Bombo Rd (KuBbiri)
P.O. Box 9519
Kampala
(Uganda)

ph. +256 41 534313
Fax +256 41 349919
Ukraine

Local distributor

Ukraine

United Arab Emirates

Local distributor

United Arab Emirates

MANARA HEALTHCARE

Concord Tower, 6th Floor
Dubai Media City
PO Box 213593, Dubai
United Arab Emirates

 

ph. +971 4 454 9712
Fax 971 4 454 2310

Asia Pacific

Asia Pacific

Australia

Local distributor

Australia

REGIONAL HEALTH CARE GROUP

3-11 Primrose Avenue Rosebery
NSW 2018 - Sydney
(Australia)

ph. +61 296624144
Fax +61 296626040
Taiwan - China

Local distributor

Taiwan - China

SUPER FORTUNE ENTERPRISE CO LTD

5 F-1 - 42 Sec.1 Ming
Sheng E. Road Jehovah Building
101 Taipei
(Taiwan)

ph. +886 225673456
Fax +886 225319231
India

Local distributor

India

Imaging Products (India) Ltd

Mumbai
(India)

ph. +91 9819725471
Fax +91 2228320208
Indonesia

Local distributor

Indonesia

PT DIPA PHARMALAB INTERSAINS

Jl. Panjang No. 10
Kebon Jeruk
Jakarta 11530
(Indonesia)

ph.  +62 215348644
Fax +62 2153676066
New Zealand

Local distributor

New Zealand

REGIONAL HEALTH LIMITED

19C Orbit Drive
Mairangi Bay
(New Zealand)

ph. +64 94140040
Fax +64 94140041
Pakistan

Local distributor

Pakistan

S. EJAZUDDIN & CO LTD

PO Box 5629 - Zia Plaza
Altaf Hussain Road
74000 Karachi
(Pakistan)

ph. +92 21212032
Fax +92 212629716
Philippines

Local distributor

Philippines

NEW MARKETLINK INTERNATIONAL CORP

Tao Corporate Centre 2291
Don Chino Roches Ave
Ext Makati City Metro
Manila (Philippines)

ph. (632) 836-5838
Singapore

Local distributor

Singapore

LF ASIA PHARMACEUTICAL DIVISION

Healthcare Distribution Centre
24 Penjuru Road (off Penjuru Close)
#03-04 CWT Commodity Hub
(Singapore 609128)

ph. +65 65097629
Thailand

Local distributor

Thailand

Interpharmacare Co., Ltd.

90 Moo 13 Soi Mahacha
Bangpleeyai
Bangplee
Samutprakarn 10540
(Thailand)

ph. + 66 2 675 9140-2
Fax + 66 2 325 0265
Vietnam

Local distributor

Vietnam

HOANG GIA INVESCO, JSC

No 74-76 Hoa Bang Str
Cau Giay
Dist Ha Noi Hanoi
(Viet Nam)

ph. +43 7846952

Litteraturförteckning

1) Produktresumé för MultiHance

2) Gadobenate dimeglumine (Gd-BOPTA). An overview

3) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.

4) Hepatobiliary MR imaging with gadolinium-based contrast agents.

5) Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.

6) Transient arterial phase respiratory motion-related artifact in MR imaging of the liver: an analysis of four different gadolinium-based contrast agents.

7) Effect of Gadoxetate Disodium on Arterial Phase Respiratory Waveforms Using a Quantitative Fast Fourier Transformation-Based Analysis.

8) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions.

9) Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.

10) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.

11) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration.

12) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

13) Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents.

14) Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents.

15) T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T.

16) A serial dilution study of gadolinium-based MR imaging contrast agents.

17) Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years.

18) Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.

19) Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.

20) Bracco Data on File

21) Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.

22) Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation.

23) Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

24) A Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.

25) Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.

26) Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.

27) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.

28) Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.

29) Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.

30) Prospective cohort study of NSF in patients with stage 3-5 CKD undergoing MRI with gadobenate or gadoteridol.

31) Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: Is there a real risk in patients with impaired renal function?

32) Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide.

Acist

ACIST® Medical Systems is a market leader in advanced contrast imaging systems for cardiovascular angiography.

 
Visit the site

ESOR

The European School ofRadiology (ESOR) is anapolitical, non-profit established and a growingproject, founded in December 2005.

 
Visit the site

MDCT.NET

Scanning technology resources for healthcare professionals.

 
Visit the site

FRISKRIVNING FRÅN ANSVAR
För att säkerställa att alla produkter eller typer av produkter beskrivna på denna webbplats används på rätt sätt måste läkaren noggrant läsa igenom produktens bipacksedel, bruksanvisning eller användarmanual före administrering till patienter. Detta gäller såväl läkemedel som utrustning. Lokala produktresuméer finns tillgängliga online för Bracco Imagings huvudsakliga produkter.

Gadoliniumretention
Efter administrering av gadobensyra kan gadolinium ansamlas i hjärnan och andra kroppsvävnader (skelett, lever, njurar, hud) och kan orsaka dosberoende ökningar i T1-viktad signalintensitet i hjärnan, särskilt i nucleus dentatus, globus pallidus och talamus. Kliniska följder är okända. De eventuella diagnostiska fördelarna med att använda MultiHance hos patienter som kommer att behöva upprepade MRT-undersökningar ska vägas mot risken för ansamling av gadolinium i hjärnan och andra vävnader.

Nedsatt njurfunktion

Före administrering av MultiHance rekommenderas att alla patienter undersöks med avseende på nedsatt njurfunktion med hjälp av laboratorieprover. Rapporter om nefrogen systemisk fibros (NSF) har förekommit i samband med användning av vissa gadoliniuminnehållande kontrastmedel hos patienter med akut eller kronisk gravt nedsatt njurfunktion (GFR < 30 ml/min/1,73 m2).

Patienter som genomgår levertransplantation löper särskilt hög risk, eftersom incidensen av akut njursvikt är hög i denna grupp. Då det finns risk för att NSF kan uppstå med MultiHance, bör administrering undvikas till patienter med gravt nedsatt njurfunktion och till patienter i den perioperativa fasen av en levertransplantation, såvida inte den diagnostiska informationen är nödvändig och inte kan fås med icke-kontrastförstärkt MRT.

Hemodialys kort tid efter administrering av MultiHance kan vara till nytta för att avlägsna MultiHance från kroppen. Det finns inga belägg som stödjer påbörjande av hemodialys för att förhindra eller behandla NSF hos patienter som inte redan genomgår hemodialys.

Äldre
Eftersom renalt clearence av gadobenatdimeglumin kan vara nedsatt hos äldre, är det särskilt viktigt att undersöka patienter som är 65 år och äldre med avseende på nedsatt njurfunktion.